Typhoon Noul (2015)

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

Retrieved on: 
Monday, October 23, 2023
Plasmodium falciparum, Research, Real-time, Trial of the century, Global health, Exhibition, Incidence, University of Notre Dame, Parasitism, Korea Human Rights Foundation, History, Prevalence, Infection, Malaria, UNITAID, RDT, R, Society, Artificial intelligence, Plasmodium vivax, Tropical medicine, Hematological Cancer Research Investment and Education Act, Clinical trial, Diagnosis, Risk, Annual report, Partnership, University of Science and Technology, Annual general meeting, Blood, University, Public, American Society of Tropical Medicine and Hygiene, Patient, University of Gondar, Pharmaceutical industry, Medical imaging, Medical device, Typhoon Noul (2015), Plasmodium, Hygiene

In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.

Key Points: 
  • In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.
  • Diagnosis of P. falciparum infections included cases with hrp2/hrp3 gene deletion with renders parasites 'invisible' to common rapid diagnostic tests.
  • Also, the diagnostic results of miLab™ in P. falciparum infected patients with hrp2/hrp3 gene deletion have been released.
  • This new study in Ethiopia and Ghana confirmed the clinical performance of miLab™ as a reliable new tool in the diagnosis of P. falciparum and P. vivax malaria.

AI Diagnostic Platform Company Noul Enters Cancer Diagnostic Business with the Launch of Cervical Cell Analysis Product

Retrieved on: 
Monday, October 9, 2023
Diagnosis, Papanikolaou, PAP, AI, Cell, Cancer, Artificial intelligence, CE, Gynaecology, Cervical cancer, LBC, Obstetrics, Woman, Blood, Medical device, Typhoon Noul (2015)

YONGIN, South Korea, Oct. 9, 2023 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), an Artificial Intelligence (AI) based blood and cancer diagnostic platform company, has newly introduced 'miLab™ Cartridge CER', a cervical cell analysis product at the International Federation of Gynecology and Obstetrics 2023.

Key Points: 
  • YONGIN, South Korea, Oct. 9, 2023 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), an Artificial Intelligence (AI) based blood and cancer diagnostic platform company, has newly introduced 'miLab™ Cartridge CER', a cervical cell analysis product at the International Federation of Gynecology and Obstetrics 2023.
  • When used with miLab™, Noul's AI-based diagnostic platform, it provides staining, imaging, and cell analysis results that assist user's decision making.
  • David Lim, CEO of Noul, said, "Through the launch of cervical cell analysis products, we have made a real step forward in the cancer diagnostic business.
  • We want to contribute to the early diagnosis of cervical cancer, the fourth largest cancer in the world for women."

AI Diagnostic Platform Company Noul Releases 2022-2023 Sustainability Report

Retrieved on: 
Tuesday, June 27, 2023
CE, Communication, IVDD, Sound, Sustainability reporting, Policy, Research, Organization, Government degree colleges in India, DART, Philosophy, KOSDAQ, Korea Human Rights Foundation, Ethics, Acquisition, Platform, Risk management, Artificial intelligence, Growth, Value, Malaria, Management, Health care, Typhoon Noul (2015)

YONGIN, South Korea, June 27, 2023 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), an Artificial Intelligence (AI) based decentralized diagnostic platform company, has released its 2022-2023 Sustainability Report, including corporate efforts and achievements in implementing sustainability.

Key Points: 
  • YONGIN, South Korea, June 27, 2023 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), an Artificial Intelligence (AI) based decentralized diagnostic platform company, has released its 2022-2023 Sustainability Report, including corporate efforts and achievements in implementing sustainability.
  • Noul has also self-disclosed the report to the DART electronic disclosure system on July 27.
  • Since 2020, Noul has issued a sustainability report every year, transparently disclosing to the stakeholders corporate activities and performances in the economic, social and environmental sector according to the company's growth stage.
  • By disclosing annual sustainability improvement plans and implementation results through sustainability report, Noul also strives to communicate responsibly with stakeholders, including investors, shareholders, customers, cooperative partners, and employees, who are participating in Noul's mission.

Biotech Company Noul Participates ASTMH, Giving Presentation at a Scientific Session

Retrieved on: 
Monday, October 31, 2022
Stockholm Environment Institute US Center, Hastings Banda, Tropical medicine, Artificial intelligence, Centers for Disease Control and Prevention, Diagnosis, View, National Institutes of Health, Multimedia, TED (conference), United States Agency for International Development, Biotechnology, History, Global health, Milab, Partnership, CEO, Patient, Society, State, Speech, Risk, Exhibition, Public sector, American Society of Tropical Medicine and Hygiene, Infection, Technology, International development, National, Innovation, Vaccine, Pharmaceutical industry, Malaria, Typhoon Noul (2015), Hygiene

Noul plans to introduce the innovativeness of malaria products and explore market opportunities in the public sector by participating in the ASTMH annual meeting.

Key Points: 
  • Noul plans to introduce the innovativeness of malaria products and explore market opportunities in the public sector by participating in the ASTMH annual meeting.
  • Also, Noul will give a speech at the Annual Innovations Pitch Competition on November 1.
  • Noul was selected within the final 5 teams for this competition, which is a TED Talk style speed presentation session presenting 'miLabTM, The Decentralized Malaria Diagnostic Platform'.
  • Meanwhile, Noul will set up a booth at this meeting and display miLabTMplatform and malaria cartridges.

Noul's Hydrogel Stamping is the potential core technology necessary for precise cancer diagnosis, study confirmed

Retrieved on: 
Wednesday, July 27, 2022
Diagnosis, Time, Research, CEO, HER2, Biomarker, Tissue, Solution, Mechanics, Massachusetts General Hospital, Health, Multimedia, Cell, KOSDAQ, Philosophy, Technology, ER, Patient, Blood, Precision medicine, Life, Breast cancer, Milab, Next Generation, Harvard Medical School, Interface, AI, IHC, Medical imaging, Medical device, Typhoon Noul (2015), Multiplexing

Hydrogel Stamping identified up to nine biomarkers that diagnose breast cancer even though the amount of antibody was reduced.

Key Points: 
  • Hydrogel Stamping identified up to nine biomarkers that diagnose breast cancer even though the amount of antibody was reduced.
  • This study confirmed the potential of Hydrogel based immunostaining as a core technology necessary for precise cancer diagnosis.
  • The study hasconcluded that the developed hydrogel stamping is a highly efficient and simple immunostaining method to stain cells and tissue samples.
  • In addition, when multiple fluorescence is applied to a hydrogel used for staining, multiple analysis is possible, enabling precise diagnosis.

Biotech Startup Noul Releases 2021 Sustainability Report

Retrieved on: 
Friday, July 8, 2022
KOSDAQ, Life, Sustainability reporting, Growth, Blood, Mechanics, DART, GRI, Philosophy, Milab, Technology, Health, Solution, AI, IPO, Multimedia, Renewable energy, Medical device, Public relations, Typhoon Noul (2015)

Disclose achievement and improvement on economic, social, and environmental commitments

Key Points: 
  • Disclose achievement and improvement on economic, social, and environmental commitments
    YONGIN, South Korea, July 8, 2022 /PRNewswire/ --Noul Co., Ltd., (376930.KR), a KOSDAQ-listed biotech startup, has released its 2021 Sustainability Report, including corporate sustainability performances.
  • Noul is a biotech startup that develops and manufactures next-generation diagnostic platforms.
  • The 2021 Noul Sustainability Report was prepared in accordance with the GRI standards.
  • The report consisted of 1) introduction of the company and product, 2) sustainability implementation system and governance for sustainability, and 3) key achievements.

Biotech Startup Noul Releases 2021 Sustainability Report

Retrieved on: 
Friday, July 8, 2022
Sustainability reporting, GRI, Growth, KOSDAQ, Blood, AI, Milab, DART, Renewable energy, Medical device, Typhoon Noul (2015)

Disclose achievement and improvement on economic, social, and environmental commitments

Key Points: 
  • Disclose achievement and improvement on economic, social, and environmental commitments
    YONGIN, South Korea, July 8, 2022 /PRNewswire/ --Noul Co., Ltd., (376930.KR), a KOSDAQ-listed biotech startup, has released its 2021 Sustainability Report, including corporate sustainability performances.
  • Noul is a biotech startup that develops and manufactures next-generation diagnostic platforms.
  • The 2021 Noul Sustainability Report was prepared in accordance with the GRI standards.
  • The report consisted of 1) introduction of the company and product, 2) sustainability implementation system and governance for sustainability, and 3) key achievements.